Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies. Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.
Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.
Thomas W. “Tim” Lyles is President of MedCare Holdings. Mr. Lyles has managed an investment portfolio for over twenty-five years, including both public and large private companies. He also serves on numerous for-profit and non-profit Boards of Directors.
Mr. Lyles’ primary responsibility is President of a private holding company, which oversees both strategic and operational issues for various portfolios companies. Mr. Lyles helped organize each fund in the predecessor MedCare Investment Funds group and served as President of each of the funds from 1991 to 2018. Mr. Lyles, through his role as President of MedCare Holdings and the predecessor, MedCare Investment Funds, has founded and established numerous health care companies.
From 1984 to 1989, Mr. Lyles was an Attorney with the law firm of Haynes and Boone in Dallas, Texas. During 1986 and 1987, he taught Real Estate Financing at Southern Methodist University in Dallas.
From 1983 to 1984, he was appointed a Briefing Attorney for the Chief Justice of the Supreme Court of Texas.
In 1983, Mr. Lyles received his J.D., Cum Laude from SMU School of Law. Prior to attending law school, he was employed by KPMG Peat Marwick. Mr. Lyles earned an accounting degree from Texas A & M University, where he graduated Summa Cum Laude in 1979.
In addition, Mr. Lyles is a retired Certified Public Accountant and has written material for the Texas State Bar and has been a speaker for the State Bar of Texas and the Dallas Bar.
Mr. Lyles is a devoted Christian who firmly believes in the objective of Hallmark University. He is married and the father of nine children.
Mike Judy is the Chief Executive Officer at Refocus-Group , Inc. He has more than 35 years of experience in the ophthalmology industry. Prior to joining Refocus, he served as Chief Commercial Officer for AcuFocus, leading the sales and marketing team as they introduced the KAMRA™ corneal inlay internationally.
Mr. Judy’s previous experience also includes his role as the Vice President of Global Surgical Marketing for Bausch and Lomb, where he was responsible for the worldwide cataract and refractive businesses. He joined B&L through the acquisition of Eyeonics, manufacturer of the Crystalens®. At Eyeonics, Mr. Judy led the sales and marketing team as the Chief Commercial Officer.
He has also served on various industry boards throughout his career and currently serves on the board of two other medical device companies.
Mr. Judy has a BA from Princeton University.
Andy is a serial entrepreneur and innovator in the healthcare space. He currently serves as the CEO of Koya Medical and serves on the board of two life science companies. Previously, he was COO at Oculeve, a first-in-class revolutionary neuromodulation platform to treat ocular disorders. The company was acquired by Allergan Plc. Prior to this, Andy developed sight-restoring implants, which have treated more than 6 million patients worldwide, including his father. The company was acquired by Santen Pharmaceuticals and licensed to Bausch & Lomb (envista® IOL). He has deep and wide experience in innovation, technology, and commercialization in the healthcare field. He received his Ph.D. in biomedical engineering from the School of Medicine at University of North Carolina-Chapel Hill, M.S. in materials science and engineering from University of Arizona, and Bachelor’s degree in chemical engineering from University of Madras. He has numerous patents and publications in healthcare innovation and leadership.
Additionally, Andy enjoys the benefits of meditation & the thrills and agonies of mountaineering. In his off-hours, he enjoys restoring and riding pre-WWII motorcycles. He is also on a quest to climb the tallest mountains in the world, though this has taken a backseat recently to focus on healthcare.
Mr. Griffin is actively involved in sourcing and diligence for private equity and debt investments.
Prior to joining WP Global, Mr. Griffin worked at Hewitt EnnisKnupp in its Global Private Equity Group. There he focused on sourcing and evaluating private equity funds and co-investments. Mr. Griffin was also involved in managing the private equity portfolios of some of Hewitt EnnisKnupp’s largest pension clients.
Mr. Griffin earned a B.A. from Augustana College and an M.B.A. from DePaul University. He is also a CFA® Charterholder.
